Ascelia Pharma AB (publ)

OM:ACE Stock Report

Market Cap: SEK 288.3m

Ascelia Pharma Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

OM:ACE Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
08 Nov 24BuySEK 54,620Peter BensonIndividual20,000SEK 2.73
17 May 24BuySEK 102,516Carin LindeIndividual11,700SEK 8.82
23 Feb 24BuySEK 62,092Peter BensonIndividual8,279SEK 7.50
09 Feb 24BuySEK 46,191Peter BensonIndividual5,255SEK 8.79
08 Jan 24BuySEK 169,500Julie BrogrenIndividual30,000SEK 5.65
08 Jan 24BuySEK 286,383Peter BensonIndividual50,000SEK 5.85

Insider Trading Volume

Insider Buying: ACE insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of ACE?
Owner TypeNumber of SharesOwnership Percentage
Private Companies-172,165-0.179%
Individual Insiders2,338,9252.43%
Institutions18,773,59719.5%
General Public75,165,67578.2%

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 184.7%.

Top Shareholders

Top 19 shareholders own 22.25% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
8.36%
Avanza Fonder AB
8,029,746SEK 24.1m345%0.03%
4.97%
Sunstone Life Science Ventures A/S
4,778,129SEK 14.3m0%44.83%
4.83%
Fourth Swedish National Pension Fund (AP4)
4,644,266SEK 13.9m71.4%0.01%
1.3%
Niels Mengel
1,252,308SEK 3.8m0%no data
0.78%
Healthinvest Partners AB
750,000SEK 2.3m0%0.07%
0.46%
FCG Fonder AB
439,267SEK 1.3m0%0.01%
0.44%
Carin Linde
425,289SEK 1.3m1.92%no data
0.36%
Magnus Corfitzen
341,745SEK 1.0m3.36%no data
0.21%
Handelsbanken Asset Management
200,609SEK 601.8k0%no data
0.17%
SEB Investment Management AB
166,008SEK 498.0k0%no data
0.13%
Peter Benson
128,534SEK 385.6k18.4%no data
0.11%
Julie Brogren
108,770SEK 326.3k7.69%no data
0.034%
Skandia Fonder AB
32,887SEK 98.7k0%no data
0.031%
Helena Wennerström
30,000SEK 90.0k0%no data
0.021%
Hans Maier
20,000SEK 60.0k0%no data
0.018%
Andreas Norlin
17,310SEK 51.9k6.34%no data
0.0089%
Marie Källström
8,509SEK 25.5k0%no data
0.0067%
Jennie Wilborgsson
6,460SEK 19.4k0%no data
0.0029%
Storebrand Fonder AB,
2,747SEK 8.2k0%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 06:47
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Ascelia Pharma AB (publ) is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Lars HevrengDanske Bank
Ludvig SvenssonPenser Access
Johan UnnerusRedeye